Indeed, in contrast with traditional vaccine adjuvants, such as aluminum compounds, that mostly stimulate humoral immune responses, targeting of DAMPs and/or PAMPs receptors to induce IFN-α/β is a very effective strategy for cell-mediated immunity and therefore an alternative as adjuvant in cancer vaccines (Figure 3). Here, IFNA2 is linked to cancer.